Northway Biotech to Create 100 Biotech Jobs Through Vilnius Facility

Northway Biotech, a leading protein-based biologics and ATMPs CDMO, is finalizing the installation of a new, 3,500-square-meter Innovative Cell Therapy and Personalized Medicine Center at the Vilnius City Innovation Industrial Park (VCIIP). 

The new center is being constructed within the territory of the Bio City III project developed by Northway, where the active expansion of biotechnology infrastructure continues. This is already the second building in this complex - a specialized biotechnology logistics center was opened here slightly earlier this year. To date, the Northway group has built two biotechnology manufacturing buildings in the Bio City I complex, while the gene therapy center Celltechna is already operating in the Bio City II territory.

"We are proud to contribute to the implementation of a project of this scale and to help build an infrastructure that strengthens Lithuania's position internationally as a hub for high tech and innovation. We highly value Northway Biotech's ambition to develop advanced medical technologies of the future in Lithuania and see great potential for this project in international markets. The life sciences industry is of utmost importance to us, and we see its tremendous potential; therefore, having the opportunity, we contribute to the creation and development of highly complex scientific and technological processes in Lithuania," says Giedrė Gečiauskienė, Board Member and Head of Client Financing at ILTE.

It is planned that the center will employ around 100 highly qualified specialists in biotechnology, bioengineering, molecular biology, and other life sciences fields.

The new infrastructure significantly contributes to Lithuania's ambition to become one of the most important life sciences hubs in the Baltic region.